Evidence map›Paper›PMID 41966643›Full record

ArticleAbdominal radiology (New York)2026

The value of enhanced CT volumetric measurement compared with RECIST 1.1 criteria in evaluating the efficacy of neoadjuvant chemotherapy combined with immunotherapy for gastric cancer.

Jie Chen, Yang Liu, Zhidong Zhang, Weishuai Zhang, Chenyu Hou, Zicheng Bao, Yushuo Cao

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie ChenDepartment of Gastrointestinal Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yang LiuDepartment of Gastrointestinal Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhidong ZhangDepartment of Gastrointestinal Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. zhang_zhi_dong@hebmu.edu.cn.
Weishuai ZhangDepartment of Gastrointestinal Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Chenyu HouDepartment of Gastrointestinal Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zicheng BaoDepartment of Gastrointestinal Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yushuo CaoDepartment of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

Hebei Provincial Department of Science and Technology No. 22377702D
6 · The paper itself

Abstract

objectiveTo explore the value of tumor volume reduction rate (VRR) measured by enhanced CT, compared with RECIST 1.1 criteria, in evaluating the efficacy of neoadjuvant chemotherapy combined with immunotherapy(NACI) for patients with locally advanced gastric cancer (LAGC), and its impact on prognosis.

methodsThis retrospective study included 107 gastric adenocarcinoma patients. VRR and RECIST 1.1 response were calculated from pre-treatment and post-treatment CT. Interobserver agreement was evaluated using the intraclass correlation coefficient(ICC), while correlation with pathological tumor regression grade (TRG) and diagnostic performance (ROC analysis) were assessed. The optimal VRR cut-off was determined. Prognostic value was evaluated via survival analysis.

resultsThe ICC for the tumor VRR was 0.966 (95% CI: 0.951-0.977), which was significantly higher than the ICC for the tumor longest diameter reduction rate (0.701, 95% CI: 0.590-0.785). VRR showed a moderate negative correlation with TRG (r= -0.389, P < 0.001), which was significantly better than the weak correlation between RECIST 1.1 and TRG (r = 0.196, P = 0.043). The area under the curve (AUC) for VRR in predicting major pathological response was significantly higher (AUC = 0.7953) than that for RECIST 1.1 (AUC = 0.6127, P = 0.0017). Survival analysis showed that grouping based on VRR (2-year PFS: 69.4% vs. 37.8%, P = 0.018) and TRG (2-year PFS: 82.8% vs. 46.2%, P = 0.0029) significantly distinguished patient prognosis, whereas RECIST 1.1 criteria did not (P = 0.74). The combined model integrating VRR and TRG failed to provide more refined prognostic stratification. Among patients with TRG 2-3, whether VRR was greater than 47.4% did not significantly stratify prognosis (P = 0.7935).

conclusions(1) The tumor VRR demonstrates significantly superior observer agreement compared to the RECIST 1.1 criteria. (2) The correlation with TRG and diagnostic efficacy of VRR before and after neoadjuvant chemotherapy combined with immunotherapy are significantly superior to RECIST 1.1 criteria. (3) Regarding 2-year PFS, both VRR and TRG are effective indicators for prognostic evaluation after this treatment regimen, whereas RECIST 1.1 criteria lack statistical significance for 2-year PFS. (4) The combined model of VRR and TRG did not enable more precise prognostic stratification, indicating a need for further research.

Indexed as

AdenocarcinomaImmunotherapyNeoadjuvant TherapyStomach NeoplasmsTomography, X-Ray ComputedAdultAgedContrast MediaFemaleHumansMaleMiddle AgedPrognosisResponse Evaluation Criteria in Solid TumorsRetrospective StudiesTreatment OutcomeContrast MediaEfficacy evaluationLocally advanced gastric cancerNeoadjuvant chemoimmunotherapyRECIST 1.1 criteriaTumor volume

Identifiers

PMID41966643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.